We have identified compounds that mimic the action of the neurotrophic factors MANF and CDNF, central regulators of cellular stress, survival, inflammation, and immune response. Our repurposed assets ERQ-01, ERQ-03, and ERQ-04, along with a new chemical entity ERQ-02, specifically target injured, stressed cells, thereby minimizing side effects. Our therapeutics will treat diabetes, Parkinson’s disease and amyotrophic lateral sclerosis (ALS) by protecting cells from death, regulating protein folding and reducing inflammation.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Von Daehnin Katu, Helsinki,uusimaa 00790,finland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://erresq.com/
- Keywords
- København V.
- HQ
- Helsinki, Uusimaa
Erresq Questions
Erresq's website is https://erresq.com/
Erresq's LinkedIn profile is https://fi.linkedin.com/company/erresq
Erresq has
1 employees.
View email and phone details for 1
employees at Erresq.
Erresq's industry is
Biotechnology Research
Erresq's top competitors are
Nola Protein Ingredients,
Ardos,
Fruit And Cookies,
Ucsf - Center For Sundhedsfaglig Forskning,
Akasi Pharma,
Akasi Pharma Ltd,
Nordic Innovation Fair,
Eresq,
Gubra,
Desentum Oy.
Erresq's categories are Biotechnology Research
Erresq's founding year is 2024
